A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
Clinical trial NCT03410875 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03410875
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-02-09
- Primary completion
- 2027-01-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.